Global IPO activity is spread across regions. In the U.S., CoreWeave and Holcim's Amrize are planning major listings. Europe sees Olam Food Ingredients gearing up for a London IPO and Northern Data for Frankfurt uplisting. Asia-Pacific is vibrant with Mixue's Hong Kong IPO seeing huge demand and JX Advanced Metals launching a large Tokyo IPO. Saudi Arabia's Umm Al Qura IPO in MENA was heavily oversubscribed, showcasing diverse IPO opportunities globally.

Global IPO markets are active with diverse listings planned across regions. Hong Kong anticipates large offerings from Kayou ($500M) and Mixue ($443M), while Malaysia's Eco-Shop eyes $212M. Oman's Asyad Shipping targets $333M, and Abu Dhabi's Alpha Data, $163M. Saudi Arabia expects a record IPO year. In the US, Redcloud revives a smaller offering. Europe sees potential listings from Swedish SBB and German OLB, with Shein considering London amidst valuation pressures. Singapore aims to attract Chinese listings.

Global IPO activity is high, especially in the US with Klarna's potential $15B IPO. Asia-Pacific is highlighted by JX Advanced Metal's potential record $3B Japan IPO and Mixue's $500M HK listing. Europe sees Novo Banco's €5B IPO and London vying for listings like IVC Evidensia and CurrentBody.

IPOX® CEO Josef Schuster commented in a recent Reuters article, "Karman Holdings valued at nearly $4 billion as shares jump in NYSE debut", offering expert analysis on Karman Holdings' successful IPO and the broader market trends favoring defense and space companies.

IPOX® CEO Josef Schuster was quoted in a recent Reuters article, "Cybersecurity firm SailPoint sets sights on $12.6 billion valuation in US IPO", providing expert insight into SailPoint's IPO and the broader implications for the technology IPO market.

Robust global IPO activity across multiple sectors: Significant US listings include SailPoint, projecting an $11.5B valuation, and DailyPay, targeting $3-4B. Honeywell's planned spin-offs represent a notable corporate restructuring. European markets are active, featuring Novo Banco and CurrentBody. In Asia, MMC Port's anticipated $1.34B Malaysian IPO highlights the region's strength. The Middle East maintains a positive outlook, with Saudi Arabia driving deal flow.

IPOX® Research Analyst Lukas Muehlbauer offered his perspective on the market debut of Maze Therapeutics (MAZE.O), a drug developer focused on chronic kidney diseases. Maze's shares saw a modest 1% increase on its Nasdaq debut, valuing the company at $690.37 million. The company’s debut follows an upsized IPO that raised $140 million.

Large potential IPOs are emerging across regions. In the US, Silvus considers a $5B valuation IPO, while Histosonics aims for a multi-billion dollar valuation. SailPoint eyes a $1B Nasdaq return. Europe sees EcoCeres planning a $5B IPO and HBX Group with strong book coverage for its Amsterdam listing.

IPOX® Research Analyst Lukas Muehlbauer offered his expert perspective on the market debut of Metsera, a GLP-1 weight-loss drug developer that achieved a $2.7 billion valuation following a 42% surge in its Nasdaq IPO. Metsera's strong performance underscores the robust investor appetite within the innovative obesity therapeutics sector.

US IPO market shows signs of heating up in early 2025 with notable confidential filings like Voyager Technologies in space and defense ($2-3B valuation). Odyssey Therapeutics (biotech), SailPoint (cybersecurity), and Metsera (obesity drugs) have also filed for IPOs on Nasdaq. While January saw a slow start, NYSE anticipates a robust IPO market recovery driven by a strong economy and potentially lower interest rates, suggesting a positive outlook for US listings in the coming months.

IPOX® CEO Josef Schuster told Reuters that Venture Global's IPO "low float" presents a "significant risk," underscoring a challenging environment for energy IPOs to achieve high premiums and highlighting the importance of float considerations in new listings.

IPOX® CEO Josef Schuster told Bloomberg that Venture Global's IPO valuation cut "jolts" the market, signaling a crucial shift: investors now demand realistic valuations and rigorous IPO deal scrutiny, emphasizing increased investor discipline as the new norm.